TyG Index Levels in Klinefelter Syndrome

Overview

It is well known that the frequency of cardiometabolic diseases are increased in patients with Klinefelter Syndrome. The triglyceride-glucose index (TyG index) is a simple surrogate marker of insulin resistance and is also associated with various cardiometabolic diseases. The aim of this study to investigate the TyG index levels and its relationship with insulin resistance and endothelial dysfunction in patients with KS.

Full Title of Study: “Triglyceride-Glucose Index Levels in Patients With Klinefelter Syndrome and Its Relationship With the Endothelial Dysfunction and Insulin Resistance: A Cross-sectional Observational Study”

Study Type

  • Study Type: Observational [Patient Registry]
  • Study Design
    • Time Perspective: Cross-Sectional
  • Study Primary Completion Date: October 1, 2014

Detailed Description

From the patient database of our Endocrinology department we randomly included a total of 30 patients with KS and 32 healthy controls in the study. All the recorded data in the database were registered under the approval of Local Ethical Committee of Gulhane School of Medicine. The clinical and laboratory parameters, TyG index, asymmetric dimethylarginine (ADMA), homeostatic model assessment of insulin resistance (HOMA-IR) and high-sensitivity C-reactive protein (hs-CRP) levels were gathered from the database and the triglyceride-glucose index was calculated by the help of pre-measured laboratory parameters.

Interventions

  • Other: no intervention
    • this study was designed as retrospective observational study

Arms, Groups and Cohorts

  • Patient
    • 30 male patients with Klinefelter syndrome who were not previously given testosterone replacement.
  • Control
    • 30 healthy control subject without diagnosis of any chronic disease

Clinical Trial Outcome Measures

Primary Measures

  • Cardiometabolic risk
    • Time Frame: 1 day
    • Triglyceride – Glucose Index

Participating in This Clinical Trial

Inclusion Criteria

  • Patients with a verified Klifelter Syndrome karyotype (all subjects included were 47, XXY) and who were not previously given testosterone replacement. Exclusion Criteria:

  • age <18 years, – acute infection, malignancy, any visceral organ dysfunction, nutritional derangements, clinical history of cardiovascular disease, cerebrovascular disease, drug use such as antidiabetic or lipid-lowering medications, or those lacking complete clinical data.

Gender Eligibility: Male

We had a patient database consisting of male patients with Klinefelter syndrome

Minimum Age: 18 Years

Maximum Age: 28 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Gulhane School of Medicine
  • Provider of Information About this Clinical Study
    • Principal Investigator: İbrahim Demirci, Dr. – Gulhane Training and Research Hospital
  • Overall Official(s)
    • Alper Sonmez, Prof., Study Director, Health Sciences University, Gulhane School of Medicine, dep. of Endocrinology and Metabolism, Turkey

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.